How Much Do Smokers Cost Employers?

Researchers at Ohio State University estimate that smoking employees cost private employers thousands more than nonsmoking employees. Read More

Jamba Juice Offering Free Kids Smoothies on July 27

Jamba Juice will be handing out free smoothies to young children this Saturday, July 27 in order to show their commitment to health. Read More

Skipping Breakfast May Increase Heart Attack Risk

A study conducted by Harvard researchers revealed that men who skip breakfast may be in more danger of getting a heart attack. Read More

5 Foods Diabetics Should NEVER Eat

Everyone knows you have to limit sugar. But these five foods -- all common in a Western diet -- can wreak havoc on your blood sugar. Read More

The Best & Worst Bedtime Snacks

If you’re tossing and turning at night, the answer to your problem might lie not in your bedroom, but in your refrigerator. Read More

Study: This Diet Can Lower Heart Attack Risk

A new study from Spain indicates that those at high risk for heart problems can reduce their risk by adopting the Mediterranean Diet. Read More

Consumer Reports: FDA Should Limit Arsenic in Rice

Consumer Reports has asked the FDA to limit arsenic levels in rice after finding measurable levels of the carcinogen in rice products. Read More

Top 10 U.S. States With the Safest Hospitals

These are the 10 states with the safest hospitals, rated from least to most safe. Read More

2012 Olympics May Spark Measles Outbreak

CDC warns that travelers returning from London could spread infections transatlantic -- and spark a public health crisis. Read More

Big Pharma Might Already Have Sights on Abbott Spinoff

Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape. Read More

Is Abbott’s Spinoff the Beginning of a Trend?

A look at Abbott Labs' (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies. Read More

Pfizer Crafting a Post-Patent Game Plan

As its Lipitor patent nears expiration, Pfizer considers new uses for Lyrica, its popular painkiller for fibromyalgia. Read More

FDA Process, Taxes Spurring Exodus of Medical Device Firms

Tax incentives for R&D, quicker FDA approvals needed to stem exodus of U.S. medical device firms, industry studies show. Read More

Heed the Red Flags at Amedisys

Congressional scrutiny of home health care specialist Amedisys, along with lowered guidance, are sure-fire signs that investors should proceed with care. Read More

Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa

On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried. Read More

Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib

Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer. Read More

Suit Asks J&J CEO to Return Part of 2010 Pay

J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say. Read More

Study Results Boost Analyst’s Forecast for Novartis Drug

An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer. Read More

FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets

Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments. Read More

Shortage of Cancer Drugs Jeopardizes Development of New Treatments

Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments. Read More